At Incisive Genetics (IG) we are focused on developing our innovative lipid nanoparticle (LNP) delivery platform for genetic therapies. We believe our proprietary platform provides a solution to the most critical challenge to effective CRISPR-based gene therapy - the effective and safe delivery of active gene editing machinery into in vivo target tissues.
We have secured the exclusive worldwide license from the University of British Columbia to the foundational technology and continue to build out our intellectual property and patent portfolio through additional research and development. We have achieved significant proof of concept data for effective in vivo gene editing and have approached our studies in a systematic way that enables us to iterate on our foundational system. We are actively using our platform to develop strategies for multiple disease indications, as well as creating new genome editing modalities. As of October 2023 we have raised seed financing of $14.5 million CAD in several rounds. For details about our most recent financing see link to "Additional Document" below.
The IG team is proud to be an emerging member of the exciting British Columbia biotechnology community and appreciates the support and encouragement from Life Sciences BC.
Biotechnology, Genomics, Therapeutics
- Cellular Medicine
- Disease Prevention
- Drug Delivery
- Drug Discovery
- Gene Therapy
- Neurological Diseases
- Product Development